Browsing Tag
preCISION
4 posts
Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus
Avacta Group’s first human AVA6103 data show controlled exatecan release and encouraging tolerability at doses above conventional exatecan’s published maximum tolerated level, strengthening the preCISION platform thesis while leaving clinical efficacy as the next decisive test.
Avacta (AIM: AVCT) clears deferred bond repayments as AVA6103 milestones shape management options
Avacta has paid another £2.61 million of its convertible bond in cash, reducing principal to £12 million, days after granting management options equivalent to about 4.1% of current issued capital.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.